CX-2051 is a monoclonal antibody conjugated commercialized by CytomX Therapeutics, with a leading Phase I program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CX-2051’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CX-2051 is expected to reach an annual total of $89 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CX-2051 Overview
CX-2051 is under development for the treatment of Ep-CAM expressing epithelial cancers, solid tumors and metastatic colorectal cancer. The therapeutic candidate is a conditionally activated antibody drug conjugate (ADC) which acts by targeting cells expressing epithelial cell adhesion molecule (EpCAM) and has a camptothecin derivative payload which acts by targeting topoisomerase-1.
CytomX Therapeutics Overview
CytomX Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. it develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company product pipeline include CX-2029, CX-904 and BMS-986288. Its pipeline carries out SqNSCLC, esophageal/GEJ and solid tumors. Cytomx also provides probody therapeutics for the treatment of cancer. It has collaborated with AbbVie, Amgen, Astellas, Regeneron and Moderna among others. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$101.2 million for the fiscal year ended December 2023 (FY2023), an increase of 90.4% over FY2022. The operating loss of the company was US$6.5 million in FY2023, compared to an operating loss of US$101.3 million in FY2022. The net loss of the company was US$0.6 million in FY2023, compared to a net loss of US$99.3 million in FY2022.
For a complete picture of CX-2051’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
